[Comment] Precision oncology in resected EGFR-mutant NSCLC

The therapeutic landscape of early-stage EGFR-mutated non-small-cell lung cancer (NSCLC) has been irreversibly transformed by adjuvant EGFR tyrosine-kinase inhibitors.1 This paradigm shift began with the ADAURA trial, which established postoperative osimertinib as the first adjuvant targeted therapy to deliver durable survival benefit in molecularly defined NSCLC.2,3 Its effects extended beyond recurrence delay, providing clear evidence that early systemic intervention can…